This company has been marked as potentially delisted and may not be actively trading. Flexion Therapeutics (FLXN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsSustainabilityTrendsBuy This Stock FLXN vs. MENS, MOR, GMTX, CALT, ZYME, SBTX, MBX, NLTX, CYBN, and BIOAShould you be buying Flexion Therapeutics stock or one of its competitors? The main competitors of Flexion Therapeutics include Jyong Biotech (MENS), MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), and BioAge Labs (BIOA). Flexion Therapeutics vs. Its Competitors Jyong Biotech MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Neoleukin Therapeutics Cybin BioAge Labs Flexion Therapeutics (NASDAQ:FLXN) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings. Do institutionals & insiders believe in FLXN or MENS? 90.0% of Flexion Therapeutics shares are owned by institutional investors. 9.1% of Flexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer FLXN or MENS? In the previous week, Jyong Biotech had 11 more articles in the media than Flexion Therapeutics. MarketBeat recorded 11 mentions for Jyong Biotech and 0 mentions for Flexion Therapeutics. Jyong Biotech's average media sentiment score of 0.31 beat Flexion Therapeutics' score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Overall Sentiment Flexion Therapeutics Neutral Jyong Biotech Neutral Which has preferable valuation & earnings, FLXN or MENS? Jyong Biotech has lower revenue, but higher earnings than Flexion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlexion Therapeutics$85.55M14.88-$113.71M-$2.01-12.59Jyong BiotechN/AN/AN/AN/AN/A Is FLXN or MENS more profitable? Jyong Biotech has a net margin of 0.00% compared to Flexion Therapeutics' net margin of -100.32%. Company Net Margins Return on Equity Return on Assets Flexion Therapeutics-100.32% N/A -44.26% Jyong Biotech N/A N/A N/A SummaryJyong Biotech beats Flexion Therapeutics on 4 of the 7 factors compared between the two stocks. Get Flexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLXN vs. The Competition Export to ExcelMetricFlexion TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27B$818.96M$5.71B$9.78BDividend YieldN/A4.84%3.77%4.10%P/E Ratio-12.591.1831.1225.06Price / Sales14.8825.64400.6388.18Price / CashN/A19.5625.2228.44Price / Book-74.436.599.255.96Net Income-$113.71M-$4.67M$3.26B$265.21M Flexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLXNFlexion TherapeuticsN/A$25.31flatN/AN/A$1.27B$85.55M-12.59257MENSJyong BiotechN/A$40.41-18.5%N/AN/A$3.77BN/A0.0031Gap UpHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsGMTXGemini TherapeuticsN/A$58.59+1.0%N/A+24.9%$2.54BN/A-58.5930CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.4982 of 5 stars$13.02+4.7%$21.43+64.6%+37.0%$907.27M$122.87M-8.68460SBTXSilverback TherapeuticsN/A$16.38-6.4%N/A+9.0%$590.63MN/A-6.7783High Trading VolumeMBXMBX Biosciences2.5609 of 5 stars$12.53+11.3%$37.63+200.3%N/A$418.80MN/A-2.7636NLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-41.4%$191.25MN/A-6.5490High Trading VolumeCYBNCybin2.4411 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$171.26MN/A-1.7450BIOABioAge LabsN/A$4.48+3.2%N/AN/A$155.59M$3.86M0.00N/A Related Companies and Tools Related Companies MENS Alternatives MOR Alternatives GMTX Alternatives CALT Alternatives ZYME Alternatives SBTX Alternatives MBX Alternatives NLTX Alternatives CYBN Alternatives BIOA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLXN) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flexion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Flexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access